The NHS has not finished the generic job

The NHS has not finished the generic job

Pitch to Healtcare Finance

A familiar line turns up whenever medicines productivity is discussed in the NHS: generic prescribing has already been done. The easy gains have gone. We need to look elsewhere. That view is comfortable, but it is wrong. Yes, generic prescribing is already the norm in large parts of primary care. NHSBSA’s generic prescribing dashboard states that 81% of all drugs in primary care are already prescribed generically. But high baseline performance does not mean the opportunity has disappeared. It means the residual opportunity is now more targeted, less visible and more operationally demanding. In other words, it is exactly the sort of opportunity that gets missed when organisations rely on slogans instead of disciplined review. The scale of the medicines spend base makes that mistake expensive. Official NHSBSA statistics show that community prescribing cost £11.2 billion in England in 2024/25 across 1.26 billion prescription items. Across primary and secondary care combined, NHS commissioners spent an estimated £20.9 billion after rebates. On a base of that size, even modest pockets of avoidable leakage justify close attention. Public NHS data already tells us the generic and off-patent story is not finished. NHSBSA’s medicines optimisation - generic prescribing dashboard says that, if it were clinically appropriate for all of its selected medicines to be prescribed generically, £17.9 million could be released nationally for reinvestment. Even the more conservative scenario — if every sub-ICB location matched the average of its best five comparable peers — still suggests £4.2 million of potential value. That is not a rounding error. It is also only one slice of the wider picture. Then there is premium-priced generic leakage. NHSBSA now maintains a dedicated dashboard because, in practice, prescribers sometimes issue a generic Drug Tariff product but add a brand name or manufacturer in brackets. In those cases the reimbursement price can follow the branded or supplier-specific list price rather than the lower generic tariff price. NHSBSA is explicit that in many instances the cost can be significantly higher than the Drug Tariff Part VIIIA price. That is the sort of operational leakage that almost never appears in a big strategic presentation, but it matters enormously when repeated over time. The off-patent wave adds a second layer. The introduction of generic dapagliflozin is a good example. NHSBSA’s SGLT2i opportunities dashboard was developed specifically to help systems monitor switching, new initiations and ongoing prescribing patterns following generic entry. But the same dashboard also contains an important warning: it does not capture clinical indication, so not all patients shown will be suitable for switching. That caveat should shape how leaders think about off-patent opportunities more broadly. These are not spreadsheet-only exercises. They are implementation programmes that sit at the intersection of finance, pharmacy, clinical governance and local pathways. This is where a lot of organisations still go wrong. They talk about generics as though the job is cultural — “encourage more generic prescribing” — when in reality the remaining value now comes from precision. Which molecules still show unexplained proprietary persistence? Which practices or sites are outliers after adjusting for plausible local context? Where are premium-priced generic patterns recurring? Which patent expiries or new generics should trigger a local implementation plan rather than passive observation? Which opportunities are large enough to justify a short, focused switch programme with dedicated support? Those are operating questions, not awareness questions. NHS England’s position supports this more disciplined approach. The archived national medicines optimisation opportunities guidance, refreshed with updated links in February 2026, remains relevant for 2026/27 and explicitly points systems back to the NHSBSA dashboards and other sources for ongoing review. The earlier 2024/25 guidance also advised ICBs to choose at least five medicines optimisation opportunities, review prescribing trend data monthly through governance structures, and drive uptake of new generics and biosimilars to at least 80% within six to twelve months where appropriate. The message is clear: public dashboards exist, but leaders are expected to turn them into managed delivery. What does that look like in practice? First, organisations need a shortlist, not a longlist. A finance or pharmacy team does not need fifty theoretical possibilities. It needs ten to twenty live opportunities ranked by value, implementation effort and confidence. Some will be simple proprietary-to-generic shifts. Some will be premium-priced generic clean-up. Some will be off-patent pathway changes. Some will be false positives that should be discarded quickly. The discipline lies in ranking and ruling out, not admiring the dashboard. Second, every shortlisted opportunity needs a bounded financial case. That means baseline spend or activity, a savings range rather than a fantasy point estimate, the main assumptions, the expected adoption route, and the reason the opportunity is clinically appropriate. Generic opportunity is often oversold because teams move straight from price gap to gross savings. Real value is net of patient suitability, workload, exceptions, and the speed at which behaviour actually changes. Third, ownership has to be explicit. Generic and off-patent opportunities die when they sit between teams. A medicines optimisation lead may spot the issue, but it may require primary care engagement, formulary changes, prescribing support, procurement input, patient communication or digital nudges to capture the value. If nobody owns delivery, the system ends up with a recurring annual rediscovery of the same opportunity. Fourth, review needs to focus on realised value, not interesting data. A good monthly pack is not just “here is the variation”. It is “here is what was approved, what changed, what did not change, and what the value impact appears to be so far”. That distinction is vital. The NHS has no shortage of intelligence. What it lacks is an operating rhythm that converts intelligence into financial movement. The strategic mistake is to treat generic and off-patent work as old news. In reality, it is one of the few medicines productivity areas where the public-data foundations are already strong, the rules are well understood, and the savings logic can be made highly concrete. It may not sound glamorous. It is still one of the most credible routes to recurring value. The NHS has not finished the generic job. It has simply moved into the stage where success depends less on broad exhortation and more on precision, governance and follow-through. That is not a smaller opportunity. It is a more professional one. Research base used in drafting